Logo do repositório
 
Publicação

Differential Expression of miRNAs in Amyotrophic Lateral Sclerosis Patients

2023-12Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorGomes, Bruno Costa
dc.contributor.authorPeixinho, Nuno
dc.contributor.authorPisco, Rita
dc.contributor.authorGromicho, Marta
dc.contributor.authorPronto-Laborinho, Ana Catarina
dc.contributor.authorRueff, José
dc.contributor.authorRueff, Jose
dc.contributor.authorde Carvalho, Mamede
dc.contributor.authorRodrigues, António Sebastião
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.institutionCentre for Toxicogenomics and Human Health (ToxOmics)
dc.contributor.pblHumana Press
dc.date.accessioned2023-09-27T22:25:13Z
dc.date.available2023-09-27T22:25:13Z
dc.date.issued2023-12
dc.descriptionFunding Information: Open access funding provided by FCT|FCCN (b-on). This research was funded by Fundação de Ciência e Tecnologia (FCT), grant numbers PTDC/MEC-NEU/31195/2017, UID/BIM/0009/2020 and UIDP/00009/2020. Publisher Copyright: © 2023, The Author(s).
dc.description.abstractAmyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control, muscle atrophy and in later stages, death. Diagnosis has an average delay of 1 year after symptoms onset, which impairs early management. The identification of a specific disease biomarker could help decrease the diagnostic delay. MicroRNA (miRNA) expression levels have been proposed as ALS biomarkers, and altered function has been reported in ALS pathogenesis. The aim of this study was to assess the differential expression of plasma miRNAs in ALS patients and two control populations (healthy controls and ALS-mimic disorders). For that, 16 samples from each group were pooled, and then 1008 miRNAs were assessed through reverse transcription-quantitative polymerase chain reaction (RT-qPCR). From these, ten candidate miRNAs were selected and validated in 35 ALS patients, 16 ALS-mimic disorders controls and 15 healthy controls. We also assessed the same miRNAs in two different time points of disease progression. Although we were unable to determine a miRNA signature to use as disease or condition marker, we found that miR-7-2-3p, miR-26a-1-3p, miR-224-5p and miR-206 are good study candidates to understand the pathophysiology of ALS.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent1652646
dc.identifier.doi10.1007/s12035-023-03520-7
dc.identifier.issn0893-7648
dc.identifier.otherPURE: 70037982
dc.identifier.otherPURE UUID: e92d027c-04d0-41f2-8e8a-f4ba7d14aa2a
dc.identifier.otherScopus: 85166515372
dc.identifier.otherPubMed: 37531027
dc.identifier.otherWOS: 001041494700003
dc.identifier.urihttp://hdl.handle.net/10362/158378
dc.identifier.urlhttps://www.scopus.com/pages/publications/85166515372
dc.language.isoeng
dc.peerreviewedyes
dc.subjectAmyotrophic lateral sclerosis
dc.subjectBiomarkers
dc.subjectEpigenetics
dc.subjectMicroRNAs
dc.subjectNeuroscience (miscellaneous)
dc.subjectNeurology
dc.subjectCellular and Molecular Neuroscience
dc.titleDifferential Expression of miRNAs in Amyotrophic Lateral Sclerosis Patientsen
dc.typejournal article
degois.publication.firstPage7104
degois.publication.issue12
degois.publication.lastPage7117
degois.publication.titleMolecular Neurobiology
degois.publication.volume60
dspace.entity.typePublication
person.familyNameRueff
person.givenNameJose
person.identifier793666
person.identifier.ciencia-id0E15-908D-EA21
person.identifier.orcid0000-0002-8456-7295
person.identifier.ridE-6426-2013
person.identifier.scopus-author-id7006536439
rcaap.rightsopenAccess
relation.isAuthorOfPublication91a3b5ac-0328-498d-8cb8-08555b202306
relation.isAuthorOfPublication.latestForDiscovery91a3b5ac-0328-498d-8cb8-08555b202306

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
s12035_023_03520_7_1_.pdf
Tamanho:
1.58 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS: ToxOmics - Artigos em revista internacional com arbitragem científica